PCSK9, first described in 2003 by Seidah et al., has been extensively studied for its role in hypercholesterolemia, as it promotes LDL receptor (LDLR) degradation through intracellular and extracellular pathways. This evidence concerns the gene LDLR and Hypercholesterolemia.